TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Clover Biopharmaceuticals Ltd. ( (HK:2197) ) has issued an update.
Clover Biopharmaceuticals Ltd. announced its annual results for the year ended December 31, 2024, revealing a significant decrease in cash and bank balances due to net cash outflows from loan repayments and investments in R&D. The company’s revenue remained stable, with increased sales of AdimFlu-S (QIS) offset by sales returns. Notably, there was a substantial decrease in other income and gains due to reduced funding recognition from CEPI. The company also reported decreased expenses across various categories, reflecting cost-saving initiatives and strategic optimization, particularly in R&D, where a focus on respiratory vaccines was prioritized.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. is a company incorporated in the Cayman Islands, focusing on the biopharmaceutical industry. Its primary products include vaccines, with a market focus on respiratory vaccine products.
YTD Price Performance: 3.32%
Average Trading Volume: 1,755,803
Technical Sentiment Signal: Buy
Current Market Cap: HK$323M
Find detailed analytics on 2197 stock on TipRanks’ Stock Analysis page.